Level C· Early human research exploring benefitsProspective StudyPubMed

Mesenchymal Stem Cells of Epicardial Adipose Tissue Show Differences in Immunophenotype and Osteogenic Potential in Patients with Coronary and Non-Coronary Heart Disease.

Gruzdeva OV., Slesareva TA., Gorbatovskaya EE., Dolmatova SE., Dyleva YA., Fanaskova EV.

Prospective Study on Cardiovascular Disease, published in Cells (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Cells (2026)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
42505380
DOI
10.3390/cells15141270

Abstract (original English)

Coronary artery calcification (CAC) is a pressing issue in cardiology. Mesenchymal stem cells (MSCs) derived from epicardial adipose tissue (EAT) may serve as a source of osteoblasts in the cardiovascular system. This study aimed to evaluate and compare the immunophenotype, proliferation, and osteogenic potential of EAT-MSCs from patients with coronary artery disease (CAD) and those with aortic stenosis (AS). The immunophenotype of MSCs was analyzed based on key markers: CD105, CD90, CD73, CD31, CD34, CD45, HLA-DR. Cell proliferation was assessed by the doubling time of the population and the specific growth rate of the cultures. The osteogenic potential was evaluated by the expression levels of the RUNX2 , SPP1 , ALPL , and BGLAP genes using PCR, as well as the protein levels in supernatants via ELISA. Qualitative detection of osteogenic proteins in cells by immunofluorescence staining. The intensity of extracellular matrix mineralization was measured using photometric methods. CD73 expression in EAT-MSCs from CAD patients was nearly 50% lower than in EAT-MSC cultures from AS patients. Following osteogenic induction, EAT-MSCs from CAD patients showed increased expression of osteogenic marker genes and their corresponding proteins. The intensity of extracellular matrix mineralization by osteoblasts derived from EAT-MSCs of CAD patients was higher than in the comparison group. E

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansMesenchymal Stem CellsOsteogenesisEpicardial Adipose TissueFemaleMaleImmunophenotypingCoronary Artery DiseaseMiddle AgedAged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research